Does Fingolimod Interact with Ocrelizumab?
Fingolimod and Ocrelizumab have a moderate drug interaction according to U.S. FDA drug labeling data. Concomitant use may cause additive immunosuppressive effects. Consider duration and mode of action when switching from fingolimod to OCREVUS. The mechanism involves additive immunosuppressive effects. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Moderate
- Fingolimod Class
- Sphingosine 1-phosphate Receptor Modulator
- Ocrelizumab Class
- CD20-directed Cytolytic Antibody
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Fingolimod and Ocrelizumab occurs because additive immunosuppressive effects. Clinically, this means concomitant use may cause additive immunosuppressive effects. consider duration and mode of action when switching from fingolimod to ocrevus. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.
What To Tell Your Doctor or Pharmacist
If you are taking Fingolimod and your doctor is considering prescribing Ocrelizumab (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider